The biopharmaceutical company said the trial of ONS-5010 to treat wet age-related macular degeneration didn't meet the pre-specified non-inferiority endpoint at week eight that was set out in a ...

A new study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet age-related macular degeneration (or "wet" AMD) fail to have vision ...

"Astellas stands by the clinical profile of Izervay, the only FDA-approved GA treatment that consistently demonstrated ...

Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...

Researchers at Johns Hopkins University have identified a process in the eye that may explain why biologic drugs for treating ...

This growth in the Age-Related Macular Degeneration market is fueled by ... in research and development investments that lead to more drug approvals and improved reimbursement policies.